Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. - Wikidata - wikimedia - TriplyDB

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

http://www.wikidata.org/entity/Q35879080

about

Ceftobiprole for the treatment of pneumonia: a European perspective Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Current and novel antibiotics against resistant Gram-positive bacteria Emerging agents to combat complicated and resistant infections: focus on ceftobiprole Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections Current challenges in treating MRSA: what are the options?Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new broad spectrum cephalosporin.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Newer developments in the treatment of Gram-positive infections.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus.Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.

P2860

Q26796463-66161C06-9013-4041-AFB1-AB2944044252 Q28066877-5D590F05-E3C6-41D6-938A-86BAFC3D440C Q28085517-4F542B39-1FB8-40BB-BD54-A27679EEBF8C Q34187667-D2FAC4A4-4E94-4B4E-A9F8-26497DCAE3B2 Q34433342-FE397D67-9EF4-42CD-926E-0BC09D7F2E9D Q35026521-C57F5DBA-81EC-4056-8D1F-24C68ED9F8EF Q35026567-BB6E0079-563F-4B34-B149-25BF3C739B46 Q35867360-9D5DE787-44D6-4042-9316-BCA684C845E4 Q36422630-30C67294-E9B2-4D98-890A-3D1DD1C4DE50 Q36785934-FA12F578-0FC2-4683-A135-C1B6DAF633E2 Q37162872-E5DF12A8-B87A-460B-8573-7035A9A6AFDE Q37259653-DF95B64C-4F7F-4C92-A042-E13E4088E9FE Q37274678-B610A1D6-8783-4D83-A400-14C92F920EC3 Q37274751-153F6A9B-6A48-4131-9D67-FFA56047D00A Q37291338-FC617777-25E5-4135-B4C9-13ABF941B8EC Q37461413-9FE5E8B1-D41D-42B8-9C0C-240C1C93241A Q37519733-2193FD03-2097-424B-8513-A0EDD432F61C Q37593094-8ADA2E43-D16F-4398-B5A6-D095FA3A51B2 Q37636151-C813B424-06D2-498D-82C3-86934CC73FBF Q37785546-B81FAE0F-F3A7-46F8-9E51-119C9DC34BF0 Q38099393-96C0FCAB-494B-4747-B5B9-28F3EBA3A9C1 Q38899451-967BED83-7105-47D5-909D-71282616675D Q39164183-CA434AC9-A406-4E03-8213-50CAD04C3ECD Q42111513-31BAC1DA-2420-4352-851D-6BFC7992582E Q42444666-085EAB42-90F7-48E8-ADB4-4DCA8ACDD473 Q43065479-3F43031E-8FDD-47BF-8829-E865DF2DBF51 Q46255695-720CDBC6-5A60-4671-B16F-6A2301F02E77

P2860

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

http://www.wikidata.org/entity/Q35879080

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Probability of target attainme ...... etic analysis of 150 subjects.

@ast

Probability of target attainme ...... etic analysis of 150 subjects.

@en

type

label

Probability of target attainme ...... etic analysis of 150 subjects.

@ast

Probability of target attainme ...... etic analysis of 150 subjects.

@en

prefLabel

Probability of target attainme ...... etic analysis of 150 subjects.

@ast

Probability of target attainme ...... etic analysis of 150 subjects.

@en

P1433

Q35879080-F4358B3A-D9C5-4119-9A3A-CBB098837E5F

P1476

Q35879080-CEB4762F-209A-415F-93A4-F0AEF3B0674D

P2093

Q35879080-2C3A5EE7-2FA2-47CD-9DBC-9A9FDBFA6073

Q35879080-53B7E61A-782B-491E-B31E-D8BF1F77848E

Q35879080-7C1EC7FC-4E5D-4EF3-8D3B-09A09C084BD1

Q35879080-8476E413-D1F9-453A-BE33-D07C24DC2E6B

Q35879080-ACAA6CA1-0F61-45E7-BBB3-447EC411796F

Q35879080-B4E5E562-0257-4861-9F21-05730C8E8632

Q35879080-E3B95304-FD87-4E7C-BF94-693CC296BB40

Q35879080-F477D5A1-C47C-411C-8E41-6F34A3CAC9B3

P2860

Q35879080-028A7806-07B8-4AE8-8825-764DAF15D964

Q35879080-02913937-10F0-4660-BE93-6EEB1664B61D

Q35879080-06246C1F-8DB8-42FA-B26E-927B183C6EB3

Q35879080-0B94C550-E0CA-4727-B4B9-C3FD2EF918C4

Q35879080-12F43676-9BD6-4678-BFDE-3C00755EDF1B

Q35879080-13827C57-BBA2-4E83-A7CF-B355DADD6388

Q35879080-1AF7BE0D-0212-4C45-B7F1-0BE776B93E80

Q35879080-1F8D91C9-A95D-48AD-8C42-1EE4F0CC61B1

Q35879080-25DADD00-635B-42E6-A444-17F8A64FFB39

Q35879080-3AA4BED3-DA9D-4BFA-8DB9-69C2B0EA0588

P304

Q35879080-8694F2FE-2715-49AC-936E-CB8642D0611F

P31

Q35879080-3A89838D-5E02-4D75-9045-DB7D851E9726

P356

Q35879080-BA293A91-50F4-49CB-AAC3-0CF3F575238C

P407

Q35879080-EF54A8BB-EA88-4172-A021-AEE3772CAC5B

P433

Q35879080-993C54FC-F784-48F8-9B2E-C66F53B5A7D0

P478

Q35879080-57145053-9999-48D8-9164-4E042000026B

P577

Q35879080-676BB7B3-26B4-4AE7-AE1A-D3F5F3FD749C

P5875

Q35879080-85340925-F6E7-4DA7-953E-E86D67E84E91

P698

Q35879080-45D434BD-FBA0-408A-931B-97F5C1C7C170

P932

Q35879080-F0A23A93-2450-4E8B-944B-0A625779B268

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Probability of target attainme ...... etic analysis of 150 subjects.

@en

P2093

Bindu P Murthy

http://www.w3.org/2001/XMLSchema#string

Gary J Noel

http://www.w3.org/2001/XMLSchema#string

George L Drusano

http://www.w3.org/2001/XMLSchema#string

Hui C Kimko

http://www.w3.org/2001/XMLSchema#string

James B Kahn

http://www.w3.org/2001/XMLSchema#string

Karen Bush

http://www.w3.org/2001/XMLSchema#string

Rienk Pypstra

http://www.w3.org/2001/XMLSchema#string

Thomas P Lodise

http://www.w3.org/2001/XMLSchema#string

P2860

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

A clone of methicillin-resistant Staphylococcus aureus among professional football players.

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.

Community-associated methicillin-resistant Staphylococcus aureus, Canada

Methicillin-resistant Staphylococcus aureus in community-acquired skin infections

Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients

Anti-MRSA agents: under investigation, in the exploratory phase and clinically available.

P304

2378-2387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01181-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6420730

http://www.w3.org/2001/XMLSchema#string

P698

17387149

http://www.w3.org/2001/XMLSchema#string

P932

1913270

http://www.w3.org/2001/XMLSchema#string